(Q44668880)

English

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection

scientific article published in November 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 December 2017

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection (English)

1 reference

Europe PubMed Central

5 December 2017

Helicobacter pylori

1 reference

based on heuristic

inferred from title

author name string

Susumu Take

1

1 reference

Europe PubMed Central

5 December 2017

Motowo Mizuno

2

1 reference

Europe PubMed Central

5 December 2017

Kuniharu Ishiki

3

1 reference

Europe PubMed Central

5 December 2017

Yasuhiro Nagahara

4

1 reference

Europe PubMed Central

5 December 2017

Tomowo Yoshida

5

1 reference

Europe PubMed Central

5 December 2017

Tomoki Inaba

6

1 reference

Europe PubMed Central

5 December 2017

Kazuhide Yamamoto

7

1 reference

Europe PubMed Central

5 December 2017

Hiroyuki Okada

8

1 reference

Europe PubMed Central

5 December 2017

Kenji Yokota

9

1 reference

Europe PubMed Central

5 December 2017

Keiji Oguma

10

1 reference

Europe PubMed Central

5 December 2017

Yasushi Shiratori

11

1 reference

Europe PubMed Central

5 December 2017

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

5 December 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

5 December 2017

98

1 reference

Europe PubMed Central

5 December 2017

11

1 reference

Europe PubMed Central

5 December 2017

2403-2408

1 reference

Europe PubMed Central

5 December 2017

Cure of duodenal ulcer associated with eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Interleukin-1 polymorphisms associated with increased risk of gastric cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Association of the interleukin-1 beta genetic polymorphism and gastric cancer risk in Japanese

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Correction: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Effect of genotypic differences in interleukin-1 beta on gastric acid secretion in Japanese patients infected with Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.07707.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2003.07707.X

1 reference

Europe PubMed Central

5 December 2017

1 reference

Europe PubMed Central

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44668880&oldid=2098847263"